

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 27 MAY 2022

The Board is pleased to announce that, all the resolutions proposed were passed by the Shareholders at the AGM held on 27 May 2022.

POLL RESULTS OF THE AGM

Reference is made to the circular of Consun Pharmaceutical Group Limited (the “**Company**”) dated 26 April 2022 (the “**Circular**”) and the notice of the annual general meeting (the “**AGM**”) dated 26 April 2022. Terms used in this announcement shall have the same meaning as those defined in the Circular unless the context requires otherwise.

The Board is pleased to announce that, all proposed resolutions as set out in the notice of AGM dated 26 April 2022 were passed by way of poll at the AGM held on 27 May 2022.

As at the date of the AGM, the total number of issued Shares of the Company was 814,378,706 Shares, which include 7,406,000 Shares repurchased by the Company (the “**Repurchased Shares**”) during the period from 1 April 2022 to 20 May 2022 but not yet cancelled. The Repurchased Shares will be cancelled in accordance with the relevant laws, regulations and policies and shall not be counted toward the total number of Shares entitling the holders to attend and vote for or against the resolutions at the AGM. As at the date of the AGM, the total number of Shares entitling the holders to attend and vote for or against the resolutions at the AGM was 806,972,706. No Shareholder entitled to attend the AGM was required to abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders is required under the Listing Rules to abstain from voting on the resolutions at the AGM. None of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

All Directors of the Board attended the AGM in person or by way of video/telephone conference.

The poll results in respect of the resolutions are as follows:

Ordinary resolutions		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To receive and approve the audited consolidated financial statements together with the Directors' report and the independent auditor's report of the Company for the year ended 31 December 2021.	451,908,116 (99.7%)	1,563,000 (0.3%)
2.	(a) To re-elect Ms. Li Qian as an executive Director.	404,267,763 (89.1%)	49,203,353 (10.9%)
	(b) To re-elect Ms. Zhang Lihua as a non-executive Director.	430,787,026 (95.0%)	22,684,090 (5.0%)
	(c) To re-elect Mr. Feng Zhongshi as an independent non-executive Director.	449,167,116 (99.1%)	4,304,000 (0.9%)
	(d) To authorize the Board to fix the Directors' remuneration.	437,037,016 (96.4%)	16,434,100 (3.6%)
3	To declare and pay to the Shareholders a final dividend of HKD0.2 per ordinary Share for the year ended 31 December 2021.	453,471,116 (100.0%)	0 (0.0%)
4	To re-appoint KPMG as the auditors of the Company and to authorize the Board to fix their remuneration.	451,961,126 (99.7%)	1,509,990 (0.3%)
5.	To grant a general and unconditional mandate to the Directors to allot, issue and deal with the additional ordinary Shares with the total number of shares not exceeding 20% of the total number of the issued Shares.	380,345,718 (83.9%)	73,125,398 (16.1%)
6.	To grant a general and unconditional mandate to the Directors to repurchase Shares with the total number of Shares not exceeding 10% of the total number of the issued Shares.	453,471,116 (100.0%)	0 (0.0%)
7.	To extend the general and unconditional mandate granted to the Directors to issue, allot and deal with additional Shares under resolution no. 5 to include the number of Shares repurchased pursuant to the general and unconditional mandate to repurchase Shares under resolution no. 6.	384,587,585 (84.8%)	68,883,531 (15.2%)

Special resolution		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
8.	To approve the proposed amendments to the existing memorandum and articles of association of the Company and to adopt the amended and restated memorandum and articles of association of the Company.	453,471,116 (100.0%)	0 (0.0%)

As more than 50% of the votes were cast in favour of each of the ordinary resolutions (resolutions no. 1 to no. 7) and more than 75% of the votes were cast in favour of the special resolution (resolution no. 8), all such resolutions were duly passed by the Shareholders. The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the AGM.

Upon the passing of the ordinary resolution of the Issuing Mandate (resolution no. 5) at the AGM, the Directors are authorized to allot, issue and otherwise deal with up to 161,394,541 unissued Shares, representing a limit equal to 20% of the total number of issued Shares entitling the holders to attend and vote at the AGM as at the date of passing such resolution, which may be extended by the Extension Mandate (resolution no. 7).

Upon the passing of the ordinary resolution of the Repurchase Mandate (resolutions no. 6) at the AGM, the Directors are authorized to repurchase a maximum of 80,697,270 Shares, representing a limit equal to 10% of the total number of issued Shares entitling the holders to attend and vote at the AGM as at the date of passing such resolution

By Order of the Board
Consun Pharmaceutical Group Limited
An Meng
Chairman

Hong Kong, 27 May 2022

As of the date of this announcement, the board of directors of the Company comprises Mr. An Meng, Ms. Li Qian, Professor Zhu Quan, and Mr. Xu Hanxing as executive directors; Ms. Zhang Lihua as a non-executive director; Mr. Su Yuanfu, Mr. Feng Zhongshi and Ms. Chen Yujun as independent non-executive directors.